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(Boostrix) is now available. The goal of this effort was to
evaluate its cost-effectiveness.
METHODS: A literature-based model was developed 
to quantify the clinical and economic costs and beneﬁts
of vaccinating parents with Boostrix following the birth
of their ﬁrst child. The model projected and compared the
number of adult infections avoided in two hypothetical
cohorts (one with and one without vaccination) of one
million parent couples over 10 years. The model also
quantiﬁed the number of pediatric infections avoided due
to reduced infectivity of vaccinated parents.
RESULTS: Immunization with Boostrix led to the fol-
lowing projected discounted beneﬁts: avoidance of 1,178
pediatric and 44,264 adult pertussis infections, 1.3 pedi-
atric encephalopathy cases, 0.4 pediatric chronic brain
damage cases, and 1.4 pediatric deaths. Vaccination led
to reductions in direct medical interventions, valued at
$15.2 million, and prevented lost productivity, valued at
$28.9 million, for a total savings of $44.1 million. Includ-
ing the cost of vaccination of $20.0 million ($10 per
adult), the net discounted savings of vaccination was esti-
mated at $24.1 million. The largest cost savings were due
to adult outpatient cases avoided (78%) and total (adult
and pediatric) hospital stays avoided (13%). The program
amounts to a net savings of $12.07 per vaccinee. In uni-
variate sensitivity analyses in which each model input was
varied by ±25 percent, the net savings per vaccinee ranged
from $5.14 to $18.99.
CONCLUSIONS: In this model, vaccinating young
parents with Boostrix appears to be a cost-saving pre-
ventive measure. Driving this result is the large cost
savings attributable to far fewer adult outpatient pertus-
sis cases.
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OBJECTIVES: Millions of cases of CAP are reported in
the US annually. The cause can be bacterial or viral. RSV
is one cause being examined more closely in adults, 
speciﬁcally in the elderly. This study estimates the direct
medical costs of treating an episode of RSV-related CAP
in adults (age ≥18 years).
METHODS: Cases were identiﬁed by principal ICD-9
diagnosis code. Residential care facility patients were
excluded. As few RSV cases (ICD-9 480.1) could be 
identiﬁed, they were combined with cases of viral CAP,
pathogen unspeciﬁed (ICD-9 480.9) to form the RSV
group. Resource use and cost proﬁles for inpatient and
outpatient management were developed and weighted to
determine a mean overall episode cost. The inpatient cost
proﬁle was comprised of hospital, post-discharge care and
readmissions within 60 days of CAP diagnosis. Inpatient
costs and discharge patterns were based on discharge data
from ﬁve US states. State ambulatory care and emergency
room databases were primary sources for outpatient pro-
ﬁles. Inpatient versus outpatient management proportions
were derived from literature. Cost estimates are reported
in 2001 US$. Charges were adjusted by means of a 
cost-to-charge ratio.
RESULTS: Of the 1,968 RSV CAP inpatient cases iden-
tiﬁed, 58% were ≥65 years old. The mean length of stay
was 5.6 days. The mean episode cost for those treated as
inpatients was $13,187. Hospital-related costs comprised
75% ($9,939) of that cost. The typical cost of outpatient
management was $550. On average, those treated 
initially as outpatients but subsequently hospitalized
accrued $13,888 per person. The mean overall cost for
an RSV-related CAP episode was $3,194.
CONCLUSIONS: RSV-related CAP cases managed as
inpatients are substantially more costly. Initiatives to treat
more patients as outpatients should lead to lowering the
overall episode cost. These costs provide valuable inputs
for economic analyses of viral CAP-related vaccines and
treatments.
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OBJECTIVES: Acute and chronic sinusitis is the ﬁfth
most common diagnosis for which antibiotics are pre-
scribed, accounting for direct annual costs of more than
$3.3 billion in the U.S. The objective of this study was to
evaluate antibiotic prescribing patterns in acute sinusitis
and compare the effectiveness and associated resource 
utilization of azithromycin versus amoxicillin, amoxi-
cillin/clavulanate, and clarithromycin.
METHODS: Between February 1, 1999 and May 31,
2000, patients with an ICD-9 code for their ﬁrst hospital
or outpatient acute sinusitis visit receiving antibiotic
therapy within 5 days of diagnosis were selected from a
managed cared database and evaluated for inclusion in
the analysis. Clinical outcomes and total resource utiliza-
tion were assessed over a 30-day period in patients
meeting eligibility criteria. Clinical outcomes were deﬁned
as: a) cured for patients receiving only one antibiotic, b)
improved for patients receiving a second course of the
initial antibiotic, and c) failed for patients receiving a
second course of a different antibiotic or hospitalized for
a respiratory tract infection.
RESULTS: A total of 27,087 eligible patients received
28,537 initial antibiotic prescriptions for acute sinusitis.
Azithromycin (17%) was the second most commonly 
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prescribed antibiotic preceded by amoxicillin (31%), 
and followed by amoxicillin/clavulanate (12%) and 
clarithromycin (7%). Efﬁcacy amongst comparators was
similar; although azithromycin treated patients had the
highest percentage of cures (86%) and fewest failures
(9%). Amoxicillin/clavulanate (83%) had the fewest
cures and clarithromycin had the most failures (11%).
Azithromycin was $35 more expensive than amoxicillin
with a total mean cost of approximately $141 compared
to clarithromycin and amoxicillin/clavulanate, which
were $80 and $89 more expensive than amoxicillin
($106), respectively. In contrast to amoxicillin/clavu-
lanate and clarithromycin, pharmacy claims accounted
for <50% of amoxicillin and azithromycin total costs.
CONCLUSIONS: With comparable efﬁcacy and resource
utilization advantages versus amoxicillin/clavulanate and
clarithromycin, this study suggests azithromycin was the
most cost-effective brand antibiotic.
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RSV is the most common cause of respiratory diseases in
children under age two worldwide. However few studies
have addressed the epidemiology and economic burden
of this infection in adults. The elderly, institutionalized
individuals and those with chronic cardiopulmonary
disease (COPD, asthma, CHF) are at high-risk for RSV
infection.
OBJECTIVES: To estimate the incidence of RSV infec-
tion, and describe healthcare resource use in a high-risk
adult population.
METHODS: A subset of the pharmetrics database (an
insurance administrative claims database) containing
records on 2.3 million patients from four large insurance
plans was utilized for this analysis. Adult subjects with
COPD, asthma or CHF claims in 1996 and 1997 were
enrolled and followed from January 1st 1998–May 31st
2001 (observation period) for new RSV diagnoses.
RESULTS: A total of 16,806 subjects (contributing
27,698.4 person-years) were studied. Sixty subjects with
RSV infection (RSV cohort) were identiﬁed during the
observation period. The incidence rate was 216.6
cases/100,000 person-years (95% CI 166.8–277.1). Of
the covariates of interest at enrollment (age, gender, other
comorbidity, steroid and oxygen use), only older age was
associated with RSV infection (P < 0.0001). The propor-
tion of subjects hospitalized for CHF/COPD/asthma was
higher in the RSV cohort after controlling for age, gender
and comorbidity (57% vs. 28%, P = 0.0005). A similar
difference was found for ICU admission (7% vs. 2%, 
P = 0.013). The median hospitalization cost in the RSV
cohort was $9,592.26, compared to $5,899.04 (P =
0.039). Outpatient visits and drug utilization were not
signiﬁcantly different between the groups.
CONCLUSIONS: This incidence rate may represent an
underestimation of the true RSV incidence as a result of
under-diagnosis in adults and lack of treatment options.
Nevertheless RSV infection in this population may repre-
sent an under appreciated cost burden to the healthcare
system. New diagnostic aids and treatment options are
needed to address this unmet medical need.
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While the hospitalization costs of severe sepsis have been
estimated, the long-term economic consequences of sepsis
survivors may be of greater importance to healthcare
decision-makers.
OBJECTIVES: The objective of this study is to estimate
and compare the long-term healthcare cost for patients
following discharge from a hospitalization for sepsis or
severe sepsis.
METHODS: This retrospective database study used
managed care claims data from 1995 to 1998 to identify
patients greater than 18 years of age with an ICD-9 code
indicating septicemia or bacteremia during a hospitaliza-
tion. Patients who experienced any signs of organ failure
during the index hospitalization as indicated by ICD-9
codes comprised the severe sepsis group; the remaining
patients comprised the sepsis group. The index hospital-
ization was deﬁned as the hospitalization containing the
ﬁrst sepsis or severe sepsis diagnosis during the above
timeframe. Patients were excluded if they did not have
any claims following hospital discharge. Log-transformed
monthly healthcare expenditures were analyzed using
analysis of variance. The propensity score method using
5 subclassiﬁcations was used to make both groups (sepsis
and severe sepsis) comparable, reducing the bias in the
analysis.
RESULTS: Of approximately 3 million members in the
database, 3,403 patients met the inclusion criteria with
2,666 (78.3%) in the sepsis group and 737 (21.7%) in
the severe sepsis group. The adjusted mean monthly cost
after discharge from the index hospitalization was
$496.63 (95%CI: $466.23–$529.01) for the sepsis group
and $571.29 (95%CI: $506.87–$643.89) for the severe
sepsis group. Severe sepsis patients were 15.0% (p =
0.043) more costly than the sepsis patients.
CONCLUSION: Interventions aimed at reducing the 
likelihood of disease progression from sepsis to severe
sepsis are likely to have beneﬁcial long-term economic
consequences for patients and healthcare systems.
